文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

头盔无创通气与经鼻高流量氧疗治疗COVID-19患者的长期结局:一项随机试验

Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial.
PubMed 文献 · J Intensive Care · 2023-05-19
一句话结论COVID-19低氧性呼吸衰竭患者使用头盔无创通气或经鼻高流量氧疗,6个月生活质量和功能结局相似,且需要有创机械通气与更差结局相关。

这项HENIVOT随机试验的预设分析评估了头盔无创通气与经鼻高流量氧疗治疗COVID-19低氧性呼吸衰竭患者的6个月结局。在80例存活患者中,71例(89%)完成随访,其中35例接受头盔无创通气、36例接受经鼻高流量氧疗。两组在生命体征、体能表现、呼吸功能、生活质量和实验室检查方面均无组间差异,仅关节痛在头盔组显著更低(16% vs 55%,p=0.002)。与成功避免有创机械通气的患者(54/71,76%)相比,接受插管的患者(17/71,24%)肺功能更差(一氧化碳弥散量中位数66%预计值 vs 80%,p=0.005)且生活质量更低(EQ-VAS 70 vs 80,p=0.01)。

要点

  • 在80例存活患者中,71例(89%)完成6个月随访:35例接受头盔无创通气、36例接受经鼻高流量氧疗。
  • 两组在生命体征(N=4项)、体能表现(N=18项)、呼吸功能(N=27项)、生活质量(N=21项)和实验室检查(N=15项)方面均无组间差异。
  • 关节痛在头盔组显著低于经鼻高流量氧疗组(16% vs 55%,p=0.002)。
  • 需要插管的患者(17/71,24%)较成功避免有创机械通气的患者(54/71,76%)肺功能更差(一氧化碳弥散量中位数66% vs 80%预计值,p=0.005)且生活质量更低(EQ-VAS 70 vs 80,p=0.01)。

适用人群与场景

  • COVID-19低氧性呼吸衰竭患者,来自HENIVOT随机试验的预设分析,评估6个月结局。
  • 完成6个月随访的存活患者共71例:头盔无创通气组35例,经鼻高流量氧疗组36例。

研究设计与关键结果

  • 研究类型:HENIVOT随机试验的预设分析,比较头盔无创通气与经鼻高流量氧疗。
  • 随访:入组后6个月评估临床状态、体能表现(6分钟步行试验和30秒椅子站立试验)、呼吸功能和生活质量(EuroQoL五维度五水平问卷、EuroQoL VAS、SF36和DSM创伤后应激障碍检查表)。
  • 80例存活患者中71例(89%)完成随访:35例接受头盔无创通气,36例接受经鼻高流量氧疗。
  • 两组在生命体征(N=4项)、体能表现(N=18项)、呼吸功能(N=27项)、生活质量(N=21项)和实验室检查(N=15项)方面均无组间差异。
  • 关节痛在头盔组显著更低(16% vs 55%,p=0.002)。
  • 一氧化碳弥散量低于预计值80%的患者比例:头盔组52% vs 经鼻高流量氧疗组63%(p=0.44);用力肺活量低于预计值80%的患者比例:头盔组13% vs 经鼻高流量氧疗组22%(p=0.51)。
  • EQ-5D-5L测试中两组疼痛程度相似(p=0.81),焦虑程度相似(p=0.81);EQ-VAS评分两组相似(p=0.27)。
  • 与成功避免有创机械通气的患者(54/71,76%)相比,接受插管的患者(17/71,24%)肺功能更差(一氧化碳弥散量中位数66%预计值[四分位距47-77] vs 80%[71-88],p=0.005)且生活质量更低(EQ-VAS:70[53-70] vs 80[70-83],p=0.01)。

证据类型、等级与局限

  • 证据类型:随机试验(HENIVOT)的预设分析。
  • 试验注册:clinicaltrials.gov NCT04502576,注册日期2020年8月6日。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在HENIVOT试验中应用的头盔无创通气可安全用于低氧性呼吸衰竭患者。
  • 需要接受有创机械通气与更差的肺功能和生活质量相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Long-term outcomes of patients treated with helmet noninvasive ventilation (NIV) are unknown: safety concerns regarding the risk of patient self-inflicted lung injury and delayed intubation exist when NIV is applied in hypoxemic patients. We assessed the 6-month outcome of patients who received helmet NIV or high-flow nasal oxygen for COVID-19 hypoxemic respiratory failure.

METHODS: In this prespecified analysis of a randomized trial of helmet NIV versus high-flow nasal oxygen (HENIVOT), clinical status, physical performance (6-min-walking-test and 30-s chair stand test), respiratory function and quality of life (EuroQoL five dimensions five levels questionnaire, EuroQoL VAS, SF36 and Post-Traumatic Stress Disorder Checklist for the DSM) were evaluated 6 months after the enrollment.

RESULTS: Among 80 patients who were alive, 71 (89%) completed the follow-up: 35 had received helmet NIV, 36 high-flow oxygen. There was no inter-group difference in any item concerning vital signs (N = 4), physical performance (N = 18), respiratory function (N = 27), quality of life (N = 21) and laboratory tests (N = 15). Arthralgia was significantly lower in the helmet group (16% vs. 55%, p = 0.002). Fifty-two percent of patients in helmet group vs. 63% of patients in high-flow group had diffusing capacity of the lungs for carbon monoxide < 80% of predicted (p = 0.44); 13% vs. 22% had forced vital capacity < 80% of predicted (p = 0.51). Both groups reported similar degree of pain (p = 0.81) and anxiety (p = 0.81) at the EQ-5D-5L test; the EQ-VAS score was similar in the two groups (p = 0.27). Compared to patients who successfully avoided invasive mechanical ventilation (54/71, 76%), intubated patients (17/71, 24%) had significantly worse pulmonary function (median diffusing capacity of the lungs for carbon monoxide 66% [Interquartile range: 47-77] of predicted vs. 80% [71-88], p = 0.005) and decreased quality of life (EQ-VAS: 70 [53-70] vs. 80 [70-83], p = 0.01).

CONCLUSIONS: In patients with COVID-19 hypoxemic respiratory failure, treatment with helmet NIV or high-flow oxygen yielded similar quality of life and functional outcome at 6 months. The need for invasive mechanical ventilation was associated with worse outcomes. These data indicate that helmet NIV, as applied in the HENIVOT trial, can be safely used in hypoxemic patients. Trial registration Registered on clinicaltrials.gov NCT04502576 on August 6, 2020.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Michi T, Mattana C, Menga LS, et al. Long-term outcome of COVID-19 patients treated with helmet noninvasive ventilation vs. high-flow nasal oxygen: a randomized trial. J Intensive Care. 2023. PMID: 37208787. doi:10.1186/s40560-023-00669-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。